TriangleDISEASE & TREATMENT SETTING
Camptosar: metastatic Carcinoma of the Colon after prior therapy
Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.
Exact scope
• Patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy.
Broader topic: Colon Cancer
- Source population
- Not part of this definition
- Disease extent
- metastatic
- Treatment line
- Not part of this definition
- Stage
- Not part of this definition
- Resectability
- Not part of this definition
Biomarkers, prior therapy and derivation
- molecular
- prior therapy
- class
- following initial fluorouracil-based therapy
- status
- required
- derivation status
- source-attested
- derivation note
- Scoped from the FDA approved indication for Camptosar (product label). Only dimensions stated in that wording are part of this definition.
- source wording
- • Patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy.
Study evidence for this setting
Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium
Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer
18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy
S1417CD Financial Impact Assessment Tool in Patients With Metastatic Colorectal Cancer
Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer
Canady Helios Cold Plasma Scalpel Treatment at the Surgical Margin and Macroscopic Tumor Sites
A Study of Efficacy and Safety of Fruquintinib (HMPL-013) in Participants With Metastatic Colorectal Cancer
Source relationships and population-mapping limitations
- bindings
- mappings
Download this complete draft source relationship record →
Preserved source evidence · Not medical advice